Literature DB >> 33486773

Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.

Hannes Hagström1,2,3, Leon A Adams4, Alina M Allen5, Christopher D Byrne6,7, Yoosoo Chang8, Henning Grønbaek9, Mona Ismail10,11, Peter Jepsen9, Fasiha Kanwal12, Jennifer Kramer12, Jeffrey V Lazarus13, Michelle T Long14, Rohit Loomba15, Philip N Newsome16,17, Ian A Rowe18, Seungho Ryu8,19, Jörn M Schattenberg20, Marina Serper21, Nick Sheron22, Tracey G Simon23,24, Elliot B Tapper25, Sarah Wild26, Vincent Wai-Sun Wong27, Yusuf Yilmaz28,29, Shira Zelber-Sagi30, Fredrik Åberg31,32.   

Abstract

BACKGROUND AND AIMS: Electronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in NAFLD, where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Diseases (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues. APPROACH AND
RESULTS: Researchers with an interest in EHR-based NAFLD research were invited to collectively define which administrative codes are most appropriate for documenting exposures and outcomes. We used a modified Delphi approach to reach consensus on several commonly encountered methodological challenges in the field. After two rounds of revision, a high level of agreement (>67%) was reached on all items considered. Full consensus was achieved on a comprehensive list of administrative codes to be considered for inclusion and exclusion criteria in defining exposures and outcomes in EHR-based NAFLD research. We also provide suggestions on how to approach commonly encountered methodological issues and identify areas for future research.
CONCLUSIONS: This expert panel consensus statement can help harmonize and improve generalizability of EHR-based NAFLD research.
© 2021 The Authors. HEPATOLOGY published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2021        PMID: 33486773      PMCID: PMC8515502          DOI: 10.1002/hep.31726

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  34 in total

1.  Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record.

Authors:  Kathleen E Corey; Uri Kartoun; Hui Zheng; Stanley Y Shaw
Journal:  Dig Dis Sci       Date:  2015-11-04       Impact factor: 3.199

2.  Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data.

Authors:  N Husain; P Blais; J Kramer; M Kowalkowski; P Richardson; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2014-08-26       Impact factor: 8.171

3.  Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Hepatology       Date:  2020-03-05       Impact factor: 17.425

4.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

5.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

6.  Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts.

Authors:  Fredrik Åberg; Pauli Puukka; Veikko Salomaa; Satu Männistö; Annamari Lundqvist; Liisa Valsta; Markus Perola; Martti Färkkilä; Antti Jula
Journal:  Hepatology       Date:  2019-10-08       Impact factor: 17.425

7.  Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database.

Authors:  David E Kaplan; Feng Dai; Ayse Aytaman; Michelle Baytarian; Rena Fox; Kristel Hunt; Astrid Knott; Marcos Pedrosa; Christine Pocha; Rajni Mehta; Mona Duggal; Melissa Skanderson; Adriana Valderrama; Tamar H Taddei
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-15       Impact factor: 11.382

8.  Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease.

Authors:  Leonard Kaps; Christian Labenz; Peter R Galle; Julia Weinmann-Menke; Karel Kostev; Jörn M Schattenberg
Journal:  United European Gastroenterol J       Date:  2020-07-23       Impact factor: 4.623

9.  Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study.

Authors:  Peter Jepsen; Hendrik Vilstrup; Lene Mellemkjaer; Ane Marie Thulstrup; Jørgen H Olsen; John A Baron; Henrik Toft Sørensen
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec

10.  Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease.

Authors:  Myriam Alexander; A Katrina Loomis; Jolyon Fairburn-Beech; Johan van der Lei; Talita Duarte-Salles; Daniel Prieto-Alhambra; David Ansell; Alessandro Pasqua; Francesco Lapi; Peter Rijnbeek; Mees Mosseveld; Paul Avillach; Peter Egger; Stuart Kendrick; Dawn M Waterworth; Naveed Sattar; William Alazawi
Journal:  BMC Med       Date:  2018-08-13       Impact factor: 8.775

View more
  5 in total

1.  Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.

Authors:  Jie Chen; Lintao Dan; Xinru Tu; Yuhao Sun; Minzi Deng; Xuejie Chen; Therese Hesketh; Ran Li; Xiaoyan Wang; Xue Li
Journal:  Hepatol Int       Date:  2022-10-04       Impact factor: 9.029

2.  Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Yi-Chuan Yu; Hung N Luu; Renwei Wang; Claire E Thomas; Nancy W Glynn; Ada O Youk; Jaideep Behari; Jian-Min Yuan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-10-14       Impact factor: 4.090

3.  Genome-Wide Association Study of NAFLD Using Electronic Health Records.

Authors:  Ewen M Harrison; Athina Spiliopoulou; Cameron J Fairfield; Thomas M Drake; Riinu Pius; Andrew D Bretherick; Archie Campbell; David W Clark; Jonathan A Fallowfield; Caroline Hayward; Neil C Henderson; Peter K Joshi; Nicholas L Mills; David J Porteous; Prakash Ramachandran; Robert K Semple; Catherine A Shaw; Cathie L M Sudlow; Paul R H J Timmers; James F Wilson; Stephen J Wigmore
Journal:  Hepatol Commun       Date:  2021-09-17

4.  Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: A nationwide population-based cohort study.

Authors:  Axel Wester; Hannes Hagström
Journal:  J Intern Med       Date:  2022-04-19       Impact factor: 13.068

5.  Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany.

Authors:  Christian Labenz; Karel Kostev; Angelo Armandi; Peter R Galle; Jörn M Schattenberg
Journal:  United European Gastroenterol J       Date:  2021-07-20       Impact factor: 6.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.